Diabetes Drug Market Report Share and Growth 2024-2032

Global Diabetes Drug Market Analysis
Market Size and Growth: The Global Diabetes Drug Market is expected to reach almost US$ 107.02 Billion by 2032, growing from US$ 63.02 Billion in 2023, with a projected CAGR of 6.06% from 2024 to 2032.
Market Overview: Diabetes is characterized by excessively high blood glucose levels and can be managed with medications such as insulin, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, and others. The market for these drugs is driven by factors such as the increasing prevalence of diabetes globally and the need for effective treatment options.
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=diabetes-drug-market-p.php
Market Drivers:
• Rising Diabetes Prevalence: The World Health Organization estimates that 422 million people worldwide have diabetes, and the disease is directly responsible for 1.5 million deaths annually, driving the demand for diabetes drugs.
• Public Awareness Campaigns: Various initiatives have been implemented to raise awareness about diabetes and its complications, increasing the demand for diabetes drugs.
• Product Approvals: The approval of new diabetes drugs, such as bexagliflozin, is expected to drive market growth by providing patients with additional treatment options.
Market Trends:
• Increasing Product Approvals: Regulatory agencies like the FDA are approving new diabetes drugs, expanding the market and providing patients with more treatment options.
• Focus on Weight-Loss Medications: Some diabetes drugs, such as Mounjaro, are also being approved for weight-loss purposes, further expanding their market potential.
• Expansion in Emerging Markets: Emerging markets like India are witnessing significant growth in the diabetes drug market due to increasing prevalence and awareness.
Key Players: Major companies in the Global Diabetes Drug Market include Novo Nordisk, AstraZeneca plc, Biocon, Sanofi, Eli Lilly, Johnson & Johnson, Bristol Myers Squibb Co., and Novartis AG.
Recent Developments
• Glenmark Pharmaceuticals Ltd.: Introduced a biosimilar version of the anti-diabetic Ligutide in India, reducing therapy costs by about 70%.
• Carmot Therapeutics: Set to be acquired by Roche for $2.7 billion, focusing on developing diabetic and anti-obesity medications.
• AstraZeneca: Entered the weight-loss drug market with an exclusive license deal for a type 2 diabetes and obesity medication in early stages of development.
• Lupin: Expanded its diabetic portfolio by acquiring Germany’s GmbH’s Ondero and Ondero Met.
Market Breakdown
Drugs Class:
1. Insulin
2. GLP-1 Receptor Agonists
3. DPP-4 Inhibitors
4. SGLT2 Inhibitors
5. Others
Diabetes Types:
1. Type 1 Diabetes
2. Type 2 Diabetes
Route of Administration:
1. Oral
2. Subcutaneous
3. Intravenous
Distribution Channels:
1. Hospital Pharmacies
2. Retail Pharmacies
3. Online Pharmacies
4. Others
1. North America
• United States
• Canada
2. Europe
• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey
3. Asia Pacific
• China
• Japan
• India
• South Korea
• Thailand
• Malaysia
• Indonesia
• Australia
• New Zealand
4. Latin America
• Brazil
• Mexico
• Argentina
5. Middle East & Africa
• Saudi Arabia
• United Arab Emirates
• South Africa
The Global Diabetes Drug Market is expected to grow significantly, driven by the increasing prevalence of diabetes, public awareness campaigns, and product approvals. Market trends include increasing product approvals, a focus on weight-loss medications, and expansion in emerging markets. Major companies are introducing innovative products and acquiring new technologies to cater to the growing demand for diabetes drugs.

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 14 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.

Share the Post:

Related Posts